| Mr Mark Lynn Duke, LCSW | |
|
132 South State, Suite 200, Salt Lake City, UT 84111-1506 | |
| (801) 240-3556 | |
| Not Available |
| Full Name | Mr Mark Lynn Duke |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 132 South State, Salt Lake City, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003035429 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 369885-3501 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Mark Lynn Duke, LCSW 11471 High Mountain Dr, Sandy, UT 84092-5675 Ph: (801) 816-1332 | Mr Mark Lynn Duke, LCSW 132 South State, Suite 200, Salt Lake City, UT 84111-1506 Ph: (801) 240-3556 |
News Archive
The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.
Malaria infections may soon be treated much more efficiently than they are at present. Researchers at the Universities of Bayreuth and Jerusalem have developed a novel drug release procedure for this purpose.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.
To help draw attention to National Child Health Day (today), the Preventive Cardiovascular Nurses Association (PCNA) has released findings from a new national consumer survey and launched a campaign to educate families about heart disease, the leading cause of death in the U.S.
› Verified 6 days ago
Mr. Glen Ray Lambert, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1361 Rebecca Cir, Salt Lake City, UT 84117 Phone: 801-272-7742 Fax: 801-322-2831 | |
Kristine Louise Nelson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: Va Slc, 500 Foothill Blvd, Salt Lake City, UT 84148 Phone: 801-582-1565 | |
Dr. Joel L Millard, DSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 150 E 700 S, Salt Lake City, UT 84111 Phone: 801-364-8080 Fax: 801-364-8098 | |
Matthew Kael Nisson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5965 S 900 E, Salt Lake City, UT 84121 Phone: 801-263-7100 | |
Michael Keith Slade, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2872 S Highland Dr, Salt Lake City, UT 84106 Phone: 801-485-8051 | |
Laura Marie Baumgart, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1390 S 1100 E Ste 204, Salt Lake City, UT 84105 Phone: 734-306-1279 |